The EOLE study was requested by French authorities at the time of new omega-3 supplementation marketing for secondary prevention of post-myocardial infarction. The main research question is to assess the impact of recommended cardiovascular drugs (beta-blockers, acetylsalicylic acid or other antiplatelet agents, statins or other lipid lowering agent, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, and omega-3 supplementation), and dietary lifestyle guidelines in real-life to all cause mortality in secondary prevention of myocardial infarction in France after 6 years of follow-up. Hospital and non-hospital cardiologists included 5527 patients from April 2006 to June 2009. Socio-demographic data, myocardial infarction characteristics, cardiovascular risk factors, history and associated cardiovascular diseases, last lab test results, cardiovascular drugs, cardiovascular rehabilitation program, tobacco use, drugs taken, hospitalisations since myocardial infarction and vital status were collected using a medical questionnaire completed at first post-myocardial infarction consultation, and a patient self-administered questionnaire filled out at inclusion, 6 month, 2, 3, 4, 5 and 6 years. At 6 years follow-up, the vital status of all patients will be ascertained from the national death registry using a standard approved national procedure whereby the national identification database is searched (decree #98-37 of 16 January 1998, modified procedure INSEE/INSERM), and failing that, through patient/relatives/physicians. An interim analysis will be planned after 3.5 years of follow-up